FreeOx Biotech has taken on AEC Partners as a strategic partner in the company to accelerate development and marketing of its drug to treat brain ischemia. Both companies are members of CataloniaBio & HealthTech.

The priority drug is Ox-01, which is about to begin phase-III clinical trials. AEC Partners analysed the brand positioning, financial needs and expected return. At the same time, negotiations are already under way with potential licensees in various world markets.

Jordi Esclusa, managing partner at AEC Partners, and Nerea Alonso, partner in the Barcelona offices of AEC Partners, explain that “It is highly satisfying to lead a project of this size from Barcelona and to help bring a drug to market in a therapeutic area with so many unmet needs, with great clinical and social impact.”

Carlos Lurigados, co-founder and CEO of FreeOx, believes that taking AEC Partners on as shareholders “will allow us to consolidate the development of Ox-01 being carried out by Dr Àngel Chamorro at Hospital Clinic, orientate it to the market and, in short, boost its value for potential licensees.”

Photo: from left to right, Jordi Esclusa, Nerea Alonso, Carlos Lurigados, Dr Ángel Chamorro and Philippe Coriat.

If you would like to learn more about AEC Partners, we recommend this video interview with CataloniaBio & HealthTech: